Target therapies with potential activity in chondrosarcoma include antiangiogenic agents, mTOR inhibitors, hedgehog inhibitors, histone deacetylase inhibitors, immunotherapy, and, more recently, IDH inhibitors. Here, MTOR is linked to chondrosarcoma.